Scientists and researchers from all over the world who work on Bacillus anthracis, the causative agent of anthrax, and B. cereus and B. thuringiensis, two closely related bacillus species, will be heading to Victoria, British Columbia, in October for the international conference known as “Bacillus ACT.”
Mount Sinai researchers describe novel mechanism cells use to recognize earliest stages of infection and how virus evades triggering an immune response
Mapping the biological machinery of the inflammatory skin disease neutrophilic dermatosis offers multiple targets for treating inflammatory disorders.
A certain cytokine, or small protein that helps cells communicate during immune responses, can control whether immune cells promote or suppress inflammatory bowel disease, a finding that could lead to new treatments, according to a study led by Georgia State University.
Denise Smith, professor of health and exercise sciences at Skidmore College, recently co-authored a study titled, “Firefighting and the Heart: Implications for Prevention.” The study was featured in the scientific journal, Circulation.
Study in Nature Nanotechnology describes new method to transform immune cells, while inside the body, into leukemia-fighting powerhouses
Nonprofit cancer immunotherapy research organization hires pharmaceutical executive to lead its clinical trials program
Dr. Alessandro Sette’s team at La Jolla Institute for Allergy and Immunology has been named Best Academic Research Team as part of the 10th Vaccine Industry Excellence Awards at this year’s World Vaccine Congress 2017 held in Washington. The ViE Awards celebrate the outstanding contributions and achievements of leaders who continually set standards of excellence and advocacy in vaccine development.
A phase one study of 11 patients with glioblastoma who received injections of an investigational vaccine therapy and an approved chemotherapy showed the combination to be well tolerated while also resulting in unexpectedly significant survival increases, researchers at the Duke Cancer Institute report.
In October 2016, Jonathan Koch, a 51-year-old entertainment executive from Los Angeles, underwent a 17-hour procedure to replace the hand he lost to a mysterious, life-threatening illness. Six months after surgery by the UCLA hand transplant team and countless hours of physical therapy, Koch continues to make remarkable strides in his recovery.
Investigators examined the relationship between injection drug use and immune activation in a sample of HIV infected and uninfected PWID. Findings suggest that efforts to encourage injection cessation or reduction in frequency can have positive health benefits through reducing immune activation.
Cancer expert Antonio Giordano, MD, PhD, Director of the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University, describes the recent progress and future possibilities of treating SCLC.
A new study has identified novel mechanisms whereby T cells may be able to distinguish an emerging class of targets specifically increased on cancer cells.
Mice in germ-free conditions and then compared to their conventionally raised counterparts. In contrast to conventionally raised mice, the germ-free mice did not show age-related increases in inflammation and a higher proportion of them lived to a ripe old age. Age is associated with an increase in levels of pro-inflammatory cytokines, such as tumor necrosis factor (TNF), in the bloodstream and tissues. It was found that germ-free mice did not have increased TNF with age.
Professor Michael Farzan, co-chair of the Department of Immunology and Microbiology on the Florida campus of The Scripps Research Institute (TSRI) has received $4.8 million in funding through a 2017 Avant-Garde Award for HIV/AIDS research from the National Institutes of Health’s National Institute on Drug Abuse (NIDA). The new funding will support a five-year project, led by Farzan, to bring a potential HIV vaccine closer to human clinical trials.
Researchers from Harvard Medical School have discovered that the body’s immune system initially detects the presence of anthrax spores by recognizing RNA molecules that coat the spores’ surface. But this prompts an unfavorable immune response that hinders the body’s fight against anthrax once the spores have germinated into live bacteria, according to the study “TLR sensing of bacterial spore-associated RNA triggers host immune responses with detrimental effects,” which will be published April 11 in The Journal of Experimental Medicine.
The discovery of a protein signature that is highly predictive of leukemia could lead to novel treatments of the leading childhood cancer, according to new study showing that competition among certain proteins causes an imbalance that leads to leukemia.
Scientists at The Scripps Research Institute (TSRI) have found a way to tether HIV-fighting antibodies to immune cells, creating a cell population resistant to the virus.
Researchers in Germany have developed a transgenic mouse that could help scientists identify new influenza virus strains with the potential to cause a global pandemic. The mouse is described in a study, “In vivo evasion of MxA by avian influenza viruses requires human signature in the viral nucleoprotein,” that will be published April 10 in The Journal of Experimental Medicine.
/PRNewswire-USNewswire/ -- Michigan State University (MSU) researchers presented promising cancer therapy results at the American Association for Cancer Research (AACR) International Meeting in Washington, DC. This novel technology, AdVCA0848, activates the stimulator of interferon genes (STING) pathway to delay tumor growth in a B16 melanoma model, promoting beneficial anti-tumor responses.
As the Zika virus continues to spread rapidly across the globe, it might pose a particular risk to people previously infected with two related viruses, dengue and West Nile, researchers at the Icahn School of Medicine at Mount Sinai have found. Their study, published in the journal Science, may help explain the severe manifestations of Zika virus infection observed in specific populations, including those in South America.
Over time, viruses have evolved very efficient methods for making us sick, but a UT Dallas researcher thinks that same efficiency could be exploited to improve human health.
A Houston Methodist-led research team showed that the systemic administration of nanoparticles triggers an inflammatory response because of blood components accumulating on their surface.
Dr. Marie Bleakley, a pediatric oncology physician-scientist at Fred Hutchinson Cancer Research Center, has received a 2017 Innovative Research Grant in immuno-oncology from Stand Up To Cancer.
New research suggests that some patients with head and neck cancers can benefit by continuing treatment with an immunotherapy drug after their tumors show signs of enlargement according to investigators at Dana-Farber Cancer Institute and other organizations.
What if your body’s ancient defenses against invading bacteria could be hijacked to help kill cancer? In a small sarcoma trial, Fred Hutch scientists led by Dr. Seth Pollack see signs of immune attack after injections of a bacteria-inspired drug.
Two doctors in the Perelman School of Medicine at the University of Pennsylvania have been awarded Immuno-Oncology Innovative Research Grants (IRG) by Stand Up to Cancer (SU2C). Michael Farwell, MD, an assistant professor of Radiology, and Gregory L. Beatty, MD, PhD, an assistant professor of Hematology Oncology, and are two of just 10 researchers to receive these grants.
An Innovative Research Grant from Stand Up to Cancer will help a University of Texas MD Anderson Cancer Center physician scientist and her team understand how the bacteria in the digestive tracts of melanoma patients affects their response to a common immunotherapy drug.
More than seven years after the start of one of the first clinical trials of the immunotherapy drug nivolumab, researchers at the Johns Hopkins Kimmel Cancer Center report that the five-year survival estimate for a limited subset of people with advanced nonsmall cell lung cancer taking the drug is 16 percent, compared with a historical survival rate for that group of 1 to 4 percent.
In the ultimate betrayal, one’s own immune system can turn against the protective sheath that envelops neurons in the brain, leaving the body paralyzed. Researchers have developed an experimental treatment that tames the wayward immune system in rodents, returning the power of movement to paralyzed mice. The approach may someday combat autoimmune diseases, such as multiple sclerosis and type 1 diabetes, in humans.
In preliminary findings that will be presented Sunday, April 2, at the American Association for Cancer Research Annual Meeting 2017, UNC Lineberger Comprehensive Cancer Center researchers report on a preclinical study into the use of nanoparticles to improve the efficacy of immunotherapy drugs known as checkpoint inhibitors.
How do health and socio-economic factors impact the nearly 1.7 million people diagnosed with cancer each year? RTI International plans to explore this through a new Robert Wood Johnson Foundation grant.
Animals can pass the damaging effects of nighttime light exposure to their offspring, a new study has found, adding to a growing body of evidence that there’s a health cost to our increasingly illuminated nights.
Mount Sinai Doctors Promote Early Detection and Free Screening
Ludwig Cancer Research released today the full scope of advances to be presented by Ludwig researchers at this year’s American Association for Cancer Research (AACR) Annual Meeting in Washington D.C., April 1-5, 2017.
Scientists from the Fred Hutchinson Cancer Research Center in Seattle are scheduled to present and discuss the latest developments in immunotherapy and proteomics at the American Association for Cancer Research Annual Meeting, Research Propelling Cancer Prevention and Cures, on April 1-5. What follows is a selection of the more than 30 Hutch presentations at the AACR gathering
Immunologic changes observed in an early study of patients with metastatic renal cell carcinoma (MRCC) raised the possibility for a larger clinical study of combination immunotherapy, according to findings reported by researchers at The University of Texas MD Anderson Cancer Center.
University of Pennsylvania cancer and HIV gene therapy pioneer Carl June, MD, has been named as a member of the 2017 class of fellows of the American Association for Cancer Research Academy.
TSRI Scientists Reveal How Viruses Disable Bacterial Immune Systems
Columbia and NewYork-Presbyterian to participate in program led by the Foundation for the National Institutes of Health Biomarkers Consortium
The National Institutes of Health has awarded a three-year, $424,081 grant to Magda El-Shenawee, electrical engineering professor, for her work on an intraoperative and rapid method of detecting positive cancer margins during conservative breast cancer surgery, or lumpectomy.
Prostate cancer, notoriously resistant to immunotherapy due to its immunologically cool nature, triggers two pathways to chill an immune attack after one immunotherapy drug fires up the immune system, researchers at The University of Texas MD Anderson Cancer Center report in Nature Medicine.
In a research effort that merged genetics, physics and information theory, a team at the Schools of Medicine and Engineering at Johns Hopkins University has added significantly to evidence that large regions of the human genome have built-in variability in reversible epigenetic modifications made to their DNA
The U.S. Food and Drug Administration yesterday granted accelerated approval to the checkpoint inhibitor Bavencio (avelumab) for the treatment of patients with metastatic Merkel cell carcinoma. Dr. Paul Nghiem, a senior investigator on the clinical trial that led to yesterday’s fast-track FDA approval and an expert on MCC is available for interviews, as is a patient who participated in the clinical trial.
Researchers predict that 13,500 new cases of colon and rectal cancers will be diagnosed in Americans under age 50 this year; in all age groups, about 100,000 cases of colon cancer and nearly 40,000 cases of rectal cancer are expected.
Colorectal cancer is the second leading cause of cancer death for men and women in the United States according to the American Cancer Society (ACS). In fact, the ACS estimates that 134,490 people in the United States were diagnosed with colorectal cancer in 2016, including 70,820 men and 63,670 women. In addition, the ACS estimates that 49,190 people, 26,020 men and 23,170 women, died from colorectal cancer in 2016.
Applications by the IMP, the Research Institute of Molecular Pathology in Vienna, were 100% successful in the latest call of the European Research Council ERC. Over the coming five years, projects by Senior Scientists Meinrad Busslinger and Elly Tanaka will be funded with 4.8 million euros.
In a new study published today in JCI Insight, UC Davis researchers have shown that combining high-intensity focused ultrasound with two immunotherapies (a PD-1 checkpoint inhibitor and TLR9 agonist) can produce excellent response rates in mouse models of epithelial cancer. They also found that, for the combination to be effective, immunotherapies must come first.
UVA researchers have again shown that a part of the body thought to be disconnected from the immune system actually interacts with it, and that discovery helps explain cases of male infertility, certain autoimmune diseases and even the failure of cancer vaccines.
Study results indicate importance of treatment based on genetic mutation rather than location of origin
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right